Renay Tyler1, Albert Barrocas2, Peggi Guenter3, Krysmaru Araujo Torres4, Matthew L Bechtold5, Lingtak-Neander Chan6, Bryan Collier7, Nilsa A Collins8, David C Evans9, Karim Godamunne10, Cindy Hamilton11, Beverly J D Hernandez12, Jay M Mirtallo3,13, William J Nadeau14, Jamie Partridge15, Moreno Perugini16, Angel Valladares17. 1. University of Maryland Medical Center, Baltimore, Maryland, USA. 2. Tulane School of Medicine, New Orleans, Louisiana, USA. 3. Clinical Practice, Quality, and Advocacy, American Society for Parenteral Nutrition, Silver Spring, Maryland, USA. 4. Nestlé Health Science, Bridgewater, New Jersey, USA. 5. Division of Gastroenterology & Hepatology, Department of Medicine University Hospital & Clinics, Columbia, Missouri, USA. 6. Department of Pharmacy, Interdisciplinary Faculty, Nutritional Sciences Program, University of Washington, Seattle, Washington, USA. 7. Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA. 8. Clinical Integration Programs, WellStar Clinical Partners Marietta, Atlanta, Georgia, USA. 9. Ohio Health Trauma and Surgical Services, Columbus, Ohio, USA. 10. North Fulton Hospitalists Group, Roswell, Georgia, USA. 11. Digestive Disease and Surgery Institute Cleveland Clinic, Cleveland, Ohio, USA. 12. Clinical Nutrition Services, Tampa General Hospital, Tampa, Florida, USA. 13. The Ohio State University, College of Pharmacy, Columbus, Ohio, USA. 14. Medical Affairs Cardinal Health, Mansfield, Massachusetts, USA. 15. Field Health Economics and Outcomes Research, Bayer Pharmaceuticals, Whippany, New Jersey, USA. 16. Global Head of Medical Affairs & Marketing Access, Nestlé Health Science, Bridgewater, New Jersey, USA. 17. Avalere Health, Washington, DC, USA.
Abstract
OBJECTIVE: Healthcare leaders seek guidance on prudent investment in programs that improve patient outcomes and reduce costs, which includes the value of nutrition therapy. The purpose of this project was to conduct an evidence review and evaluate claims analyses to understand the financial and quality impact of nutrition support therapy on high-priority therapeutic conditions. METHODS: Task 1 included a review of existing literature from 2013 to 2018 to identify evidence that demonstrated the clinical and economic impact of nutrition intervention on patient outcomes across 13 therapeutic areas (TAs). In Task 2, analytic claims modeling was performed using the Medicare Parts A and B claims 5% sample dataset. Beneficiaries diagnosed in 5 selected TAs (sepsis, gastrointestinal [GI] cancer, hospital-acquired infections, surgical complications, and pancreatitis) were identified in the studies from Task 1, and their care costs were modeled based on nutrition intervention. RESULTS: Beginning with 1099 identified articles, 43 articles met the criteria, with a final 8 articles used for the Medicare claims modeling. As examples of the modeling demonstrated, the use of advanced enteral nutrition formula could save at least $52 million annually in a sepsis population. The total projected annual cost savings from the 5 TAs was $580 million. CONCLUSION: Overall, optimization of nutrition support therapy for specific patient populations is estimated to reduce Medicare spending by millions of dollars per year across key TAs. These findings demonstrate the evidence-based value proposition of timely nutrition support to improve clinical outcomes and yield substantial cost savings.
OBJECTIVE: Healthcare leaders seek guidance on prudent investment in programs that improve patient outcomes and reduce costs, which includes the value of nutrition therapy. The purpose of this project was to conduct an evidence review and evaluate claims analyses to understand the financial and quality impact of nutrition support therapy on high-priority therapeutic conditions. METHODS: Task 1 included a review of existing literature from 2013 to 2018 to identify evidence that demonstrated the clinical and economic impact of nutrition intervention on patient outcomes across 13 therapeutic areas (TAs). In Task 2, analytic claims modeling was performed using the Medicare Parts A and B claims 5% sample dataset. Beneficiaries diagnosed in 5 selected TAs (sepsis, gastrointestinal [GI] cancer, hospital-acquired infections, surgical complications, and pancreatitis) were identified in the studies from Task 1, and their care costs were modeled based on nutrition intervention. RESULTS: Beginning with 1099 identified articles, 43 articles met the criteria, with a final 8 articles used for the Medicare claims modeling. As examples of the modeling demonstrated, the use of advanced enteral nutrition formula could save at least $52 million annually in a sepsis population. The total projected annual cost savings from the 5 TAs was $580 million. CONCLUSION: Overall, optimization of nutrition support therapy for specific patient populations is estimated to reduce Medicare spending by millions of dollars per year across key TAs. These findings demonstrate the evidence-based value proposition of timely nutrition support to improve clinical outcomes and yield substantial cost savings.
Authors: Kurt Hong; Suela Sulo; William Wang; Susan Kim; Laura Huettner; Rose Taroyan; Kirk W Kerr; Carolyn Kaloostian Journal: J Prim Care Community Health Date: 2021 Jan-Dec
Authors: Matthew C Bozeman; Laura L Schott; Amarsinh M Desai; Mary K Miranowski; Dorothy L Baumer; Cynthia C Lowen; Zhun Cao; Krysmaru Araujo Torres Journal: J Health Econ Outcomes Res Date: 2022-07-01